GYNE-LOTRIMIN 3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 (GYNE-LOTRIMIN 3).
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
| Metabolism | Minimal systemic absorption after intravaginal administration; primarily metabolized in the liver via hepatic microsomal enzymes. |
| Excretion | Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug. |
| Half-life | Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance. |
| Protein binding | Clotrimazole is 90–95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.1–0.2 L/kg after systemic absorption; however, for vaginal administration, systemic absorption is negligible, so Vd is not clinically meaningful. |
| Bioavailability | Systemic bioavailability after intravaginal administration is <0.5% due to poor absorption through vaginal mucosa and extensive first-pass metabolism. |
| Onset of Action | Onset of symptomatic relief (itching, discharge) occurs within 24–72 hours after intravaginal insertion; significant clinical improvement typically seen within 3 days. |
| Duration of Action | Therapeutic effect persists for 7–14 days after a single 3-day course, based on continued antifungal activity and resolution of infection; recurrence possible if reinfection occurs. |
| Molecular Weight | 344.84 |
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment (Child-Pugh A, B, or C). |
| Pediatric use | Intravaginal: children ≥12 years: same as adult dosing (3-day regimen). Children <12 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use same regimen as younger adults. Consider renal and hepatic function, though no adjustment needed. |
| 1st trimester | Limited data; topical clotrimazole is considered low risk but avoid first trimester unless essential. |
| 2nd trimester | Generally considered safe; no known teratogenic effects. |
| 3rd trimester | Generally considered safe; short-term use near term is acceptable. |
Clinical note
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 (GYNE-LOTRIMIN 3).
| Placental transfer | Negligible due to low systemic absorption after topical application. |
| Breastfeeding | Minimal systemic absorption; compatible with breastfeeding. Apply to nipple area only if necessary and remove before nursing. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to clotrimazole or any component
| Precautions | Do not use if abdominal pain, fever, or foul-smelling discharge is present., Discontinue if sensitivity or irritation occurs., Not for prevention of sexually transmitted diseases. |
| Food/Dietary | No known food interactions. Avoid alcohol consumption as it may worsen side effects (e.g., nausea). |
| Clinical Pearls | GYNE-LOTRIMIN 3 contains clotrimazole 200 mg vaginal tablets. For uncomplicated vulvovaginal candidiasis, 3-day regimen is as effective as 7-day. Avoid use in pregnant patients; 7-day regimen preferred. May weaken latex condoms and diaphragms. |
Loading safety data…
| L1 (Safe) |
| Teratogenic Risk | Clotrimazole (active ingredient) is classified as Pregnancy Category B. There is no evidence of teratogenicity in animal studies; limited human data show no increased risk of major birth defects. Avoid intravaginal use during first trimester unless clearly needed; use during second and third trimesters is generally considered safe. |
| Fetal Monitoring | No specific maternal or fetal monitoring required for standard use. In cases of prolonged use or high-dose regimens, monitor for local irritation or hypersensitivity reactions. |
| Fertility Effects | No known adverse effects on fertility. Clotrimazole does not affect ovulation, implantation, or spermatogenesis when used vaginally. |
| Patient Advice | Insert one tablet high into the vagina at bedtime for 3 consecutive nights. · Wash hands before and after insertion. · Do not use tampons, douche, or have vaginal intercourse during treatment. · Continue treatment even during menstruation; do not use a tampon. · If symptoms persist after completing treatment, consult healthcare provider. |